Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

7700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-22

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of abdominal-pelvic region radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the abdominal-pelvic region.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiotherapy Treatments for the Treatment of Thoracic District Tumors

NCT06335290

Thoracic Neoplasms

RECRUITING

Radiotherapy Treatments for Neoplasms in the Head and Neck Region

NCT06335342

Head and Neck Neoplasms

RECRUITING

Radiotherapy Treatments for Neoplasms of the Limbs

NCT06335251

Bone Neoplasms Bone Metastases

RECRUITING

Short Course Radiation Therapy in Palliative Treatment of Pelvic Cancer

NCT03804333

Pelvic Cancer Radiotherapy Palliative Care

UNKNOWN NA

Evaluation of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Uterine Neoplasms

NCT06774482

Uterine Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 60% of patients with neoplasms receive radiotherapy as part of their oncological treatment.

Various primary tumors as well as metastases of various origins can be localized in the abdominal-pelvic anatomical region.

Patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments. Treatment choice is usually established following multidisciplinary discussions, based on disease characteristics and stage, concurrent pathologies and pharmacological treatments, patient preferences, and functional aspects.

Data collection related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself. The availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness, aiming to identify the best treatment for these oncological pathologies.

This project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms of the abdominal-pelvic region for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time, and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Cancer Pelvic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiotherapy to abdominal-pelvic region

Collection of data of patients receiving RadioTherapy (RT) to abdominal-pelvic region

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the abdominal-pelvic region for:

Primary tumors of the gastrointestinal tract, Primary tumors of the male and female reproductive systems, Primary tumors of the urinary system, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system, Skin tumors, Secondary abdominal-pelvic localizations of various origins, Primary or secondary bone or soft tissue lesions of the lumbosacral spine and pelvis.
2. Signed informed consent